Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harbeck

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelP Hadji, R E Coleman, C Wilson, et al.
ESMO Open|August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)O Gluz, U Nitz, M Christgen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2017
Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centresP A van Dam, M Tomatis, L Marotti, et al.
ESMO Open|December 23, 2022
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study GroupS P Gampenrieder, V Dezentjé, M Lambertini, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.
ESMO Open|May 25, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancerK H Park, S Loibl, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
ESMO Open|May 13, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancerS-A Im, A Gennari, Y H Park, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelP Hadji, R E Coleman, C Wilson, et al.
ESMO Open|August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)O Gluz, U Nitz, M Christgen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2017
Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centresP A van Dam, M Tomatis, L Marotti, et al.
ESMO Open|December 23, 2022
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study GroupS P Gampenrieder, V Dezentjé, M Lambertini, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.
ESMO Open|May 25, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancerK H Park, S Loibl, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
ESMO Open|May 13, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancerS-A Im, A Gennari, Y H Park, et al.
Pageof 15